Atea Pharmaceuticals (AVIR) Current Assets (2019 - 2026)

Atea Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $263.2 million for Q1 2026.

• In Q1 2026, Current Assets fell 39.31% year-over-year to $263.2 million; the TTM figure through Mar 2026 stood at $263.2 million (down 39.31% YoY), while the FY2025 annual figure was $311.0 million, down 32.74% from the prior year.
• Current Assets for Q1 2026 stood at $263.2 million, down from $311.0 million in the prior quarter.
• The five-year high for Current Assets was $713.2 million in Q1 2022, with the low at $263.2 million in Q1 2026.
• The 5-year median for Current Assets is $548.8 million (2024), against an average of $525.1 million.
• The sharpest annual moves came in 2023 and 2026: Current Assets fell 9.95% in 2023, then slumped 39.31% in 2026.
• Atea Pharmaceuticals' Current Assets stood at $660.9 million in 2022, then decreased by 10.66% to $590.5 million in 2023, then slipped by 21.7% to $462.4 million in 2024, then sank by 32.74% to $311.0 million in 2025, then fell by 15.37% to $263.2 million in 2026.
• Business Quant data shows AVIR's Current Assets at $263.2 million in Q1 2026, $311.0 million in Q4 2025, and $336.1 million in Q3 2025.